Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model

被引:375
作者
Takagi, Y
Takahashi, J
Saiki, H
Morizane, A
Hayashi, T
Kishi, Y
Fukuda, H
Okamoto, Y
Koyanagi, M
Ideguchi, M
Hayashi, H
Imazato, T
Kawasaki, H
Suemori, H
Omachi, S
Iida, H
Itoh, N
Nakatsuji, N
Sasai, Y
Hashimoto, N
机构
[1] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Sakyo Ku, Kyoto 6068507, Japan
[2] RIKEN, Ctr Dev Biol, Organogenesis & Neurogenesis Grp, Kobe, Hyogo, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto, Japan
[4] Natl Cardiovasc Ctr, Dept Expt Radiol, Osaka, Japan
[5] Kyoto Univ, Inst Frontier Med Sci, Dept Dev & Differentiat, Kyoto, Japan
[6] Kyoto Univ, Dept Med Embryol & Neurobiol, Kyoto, Japan
[7] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto, Japan
关键词
D O I
10.1172/JCI200521137
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Parkinson disease (PD) is a neurodegenerative disorder characterized by loss of midbrain dopaminergic (DA) neurons. ES cells are currently the most promising donor cell source for cell-replacement therapy in PD. We previously described a strong neuralizing activity present on the surface of stromal cells, named stromal cell-derived inducing activity (SDIA). In this study, we generated neurospheres composed of neural progenitors from monkey ES cells, which are capable of producing large numbers of DA neurons. We demonstrated that FGF20, preferentially expressed in the substantia nigra, acts synergistically with FGF2 to increase the number of DA neurons in ES cell-derived neurospheres. We also analyzed the effect of transplantation of DA neurons generated from monkey ES cells into 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated (MPTP-treated) monkeys, a primate model for PD. Behavioral studies and functional imaging revealed that the transplanted cells functioned as DA neurons and attenuated MPTP-induced neurological symptoms.
引用
收藏
页码:102 / 109
页数:8
相关论文
共 53 条
[1]  
AKAI T, 1995, J PHARMACOL EXP THER, V273, P309
[2]   Stem cells in the treatment of Parkinson's disease [J].
Arenas, E .
BRAIN RESEARCH BULLETIN, 2002, 57 (06) :795-808
[3]  
BANKIEWICZ KS, 1986, LIFE SCI, V39, P7, DOI 10.1016/0024-3205(86)90431-5
[4]   Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back [J].
Bergman, H ;
Deuschl, G .
MOVEMENT DISORDERS, 2002, 17 :S28-S40
[5]  
Betarbet R, 1997, J NEUROSCI, V17, P6761
[6]   Neural transplantation for the treatment of Parkinson's disease [J].
Björklund, A ;
Dunnett, SB ;
Brundin, P ;
Stoessl, AJ ;
Freed, CR ;
Breeze, RE ;
Levivier, M ;
Peschanski, M ;
Studer, L ;
Barker, R .
LANCET NEUROLOGY, 2003, 2 (07) :437-445
[7]   Cell replacement therapies for central nervous system disorders [J].
Björklund, A ;
Lindvall, O .
NATURE NEUROSCIENCE, 2000, 3 (06) :537-544
[8]   Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model [J].
Björklund, LM ;
Sánchez-Pernaute, R ;
Chung, SM ;
Andersson, T ;
Chen, IYC ;
McNaught, KS ;
Brownell, AL ;
Jenkins, BG ;
Wahlestedt, C ;
Kim, KS ;
Isacson, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (04) :2344-2349
[9]   A PRIMATE MODEL OF PARKINSONISM - SELECTIVE DESTRUCTION OF DOPAMINERGIC-NEURONS IN THE PARS COMPACTA OF THE SUBSTANTIA NIGRA BY N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE [J].
BURNS, RS ;
CHIUEH, CC ;
MARKEY, SP ;
EBERT, MH ;
JACOBOWITZ, DM ;
KOPIN, IJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14) :4546-4550
[10]  
Ciccolini F, 1998, J NEUROSCI, V18, P7869